Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Metastatic Sarcoma, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Resectable Colorectal Carcinoma, Resectable Liver and Intrahepatic Bile Duct Carcinoma, Resectable Pancreatic Carcinoma, Resectable Sarcoma, Stage IV Colorectal Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Pancreatic Carcinoma, Resectable Brain Neoplasm, Resectable Breast Carcinoma, Resectable Gastric Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Navigation to Successful Colorectal Cancer Screening

NCT02192034
Conditions
Colorectal Cancer Screening
Interventions
Navigation
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7
Interventions
Oxaliplatin, Trifluridine and Tipiracil Hydrochloride
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Elizabeth, New Jersey • Lakewood, New Jersey • Livingston, New Jersey + 3 more
Conditions
Colorectal Cancer, Colon Polyps, Adenomatous Polyp of Colon
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 49 Years
Enrollment
1,623 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
6
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 2 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Bundled Cancer Screening and Genetic Services Navigation

NCT07228000
Conditions
Breast Cancer Screening, Colon Cancer Screening, Genetics Predisposition
Interventions
Breast cancer screening navigation, Multicancer screening navigation, Usual care genetics referral, Pretest education + usual care genetics referral
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
45 Years to 74 Years · Female only
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Newark, Delaware • Washington D.C., District of Columbia
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Conditions
Colorectal Cancer
Interventions
capecitabine, celecoxib, irinotecan hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
Conditions
Colon Cancer
Interventions
Colorectal cancer screening pamphlet
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
45 Years and older
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
8
States / cities
La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Conditions
Breast Cancer, Colon Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
15
States / cities
Orange, California • Colorado Springs, Colorado • Hartford, Connecticut + 12 more
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Conditions
Colon Cancer, Colorectal Cancer
Interventions
capecitabine, imatinib mesylate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
SNS-101 (anti-VISTA), Cemiplimab
Drug
Lead sponsor
Sensei Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
Conditions
Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Pain, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Tucson, Arizona • Antioch, California • Fremont, California + 45 more
Conditions
Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
Interventions
Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Terminated Phase 2 Interventional Results available

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571
Conditions
Metastatic Colorectal Cancer
Interventions
sunitinib and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Quality of Life, Small Intestine Cancer
Interventions
bowel obstruction management, quality-of-life assessment
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Improving Colon Cancer Screening for Diverse Populations

NCT02054598
Conditions
Colorectal Cancer
Interventions
Decision aid and navigation
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • Charlotte, North Carolina
Conditions
Solid Tumor, Colorectal Cancer, Endometrial Cancer
Interventions
DS-7423
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Nashville, Tennessee
Conditions
Colorectal Cancer
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more